Amarin Corporation plc
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a AMRN research report →
About the company
Amarin Corporation plc is a pharmaceutical firm dedicated to the research, development, and commercialization of therapeutic solutions for cardiovascular diseases. Its operations span several international regions, including the United States, Germany, Canada, Lebanon, and the United Arab Emirates. The company's flagship product is VASCEPA, an omega-3 fatty acid formulation available by prescription only.
- CEO
- Aaron D. Berg
- IPO
- 1993
- Employees
- 275
- HQ
- Dublin, IE
Price Chart
- Market Cap
- $338.58M
- P/E
- -10.13
- P/S
- 1.58
- P/B
- 0.76
- EV/EBITDA
- -41.46
- Div Yield
- 0.00%
- Gross Margin
- 52.48%
- Op Margin
- -17.38%
- Net Margin
- -15.64%
- ROE
- -7.34%
- ROIC
- -7.76%
- Revenue
- $213.65M · -6.55%
- Net Income
- $-38,798,000 · 52.79%
- EPS
- $-1.80 · 55.00%
- Op Income
- $-13,941,000
- FCF YoY
- 121.74%
- 52W High
- $20.90
- 52W Low
- $12.96
- 50D MA
- $14.86
- 200D MA
- $15.44
- Beta
- 0.82
- Avg Volume
- 79.51K
Get TickerSpark's AI analysis on AMRN
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 26, 26 | Berg Aaron | other | 6,250 |
| Jun 26, 26 | Berg Aaron | other | 3,197 |
| Jun 26, 26 | Berg Aaron | other | 6,250 |
| Apr 18, 26 | Bonfiglio Patrice Eadon | other | 838 |
| Apr 18, 26 | Bonfiglio Patrice Eadon | other | 838 |
| Apr 18, 26 | Bonfiglio Patrice Eadon | other | 403 |
| Apr 18, 26 | Cohen Paul | other | 838 |
| Apr 18, 26 | Cohen Paul | other | 838 |
| Apr 18, 26 | Cohen Paul | other | 403 |
| Apr 18, 26 | Sterling Louis III | other | 838 |
Our AMRN coverage
Recent articles, reports, and earnings notes.
No research on AMRN yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate AMRN report →Similar companies
Peers in the same neighborhood.